Brought to you by:
The top 10 most popular Vascular Specialist stories in January
January’s top 10 includes “Our forever plague,” a combined editorial by Malachi Sheahan III, MD, our medical editor, on fake news and science, and coverage of the U.S. investigational device exemption (IDE) Aortic Research Consortium and how the chief investigators…
Index atherectomy interventions for claudication ‘is associated with higher’ reintervention rates vs. other technologies
Atherectomy use during index peripheral vascular interventions in claudicants is associated with higher reintervention rates when compared to other technologies, a newly unveiled study by Caitlin Hicks, MD, and colleagues at Johns Hopkins Hospital in Baltimore, Maryland, shows. The researchers…
Cook Medical receives FDA breakthrough designation for new drug-eluting stent
Cook Medical has received Breakthrough Device designation from the Food and Drug Administration (FDA) on a new drug-eluting stent (DES) for below the knee (BTK). This new stent is designed to treat patients suffering from chronic limb-threatening ischemia (CLTI). The Breakthrough…
ISET 2022 audience hears latest data on endovascular therapies
At this year’s International Symposium on Endovascular Therapy (ISET), being held Jan. 16–19 in Hollywood, Florida, experts presented an array of late-breaking trial results on topics ranging from venous stenting to abdominal aortic aneurysm (AAA) sac sealing. Waseem Wahood, MS, a…
CSI announces development of IVL technology for the treatment of PAD
Cardiovascular Systems (CSI) recently announced that it has made significant progress towards the commercialization of its intravascular lithotripsy (IVL) system for the treatment of calcific peripheral arterial disease (PAD). A company press release notes that feasibility testing of a proprietary…
SVS PAD course postponed
The new Society for Vascular Surgery (SVS) Peripheral Arterial Disease (PAD) Skills Course has been postponed amid the COVID-19 pandemic recent surge in cases, the Society has announced. The course—which had been set to run Feb. 11–12—will now take place…
Smoking status ‘should not deter nor delay’ endovascular intervention in femoropopliteal vessels
Smoking does not seem to affect reocclusion rates, interval to reintervention and the total number of interventions in peripheral arterial disease (PAD) patients with stents in the femoropopliteal segment, new research showed. These were among the findings delivered by Sascha…
Learn by doing at February SVS PAD workshop
The Society for Vascular Surgery (SVS) Peripheral Arterial Disease (PAD) Workshop in February will feature four hours of hands-on surgical skills training, on 10 different facets of PAD treatment. “We are offering the chance for surgeons to be trained by…
Rise in cardiovascular disease, vascular surgeon burnout presents a public health crisis, Western Vascular Society hears
Cases of cardiovascular disease are rising across the U.S., with large disparities seen in ethnic groups and poorer geographical areas. In combination with increased burnout in the vascular workforce, this has led to a public health crisis that requires immediate…
Endologix announces completion of enrollment in TORUS 2 study for PAD in SFA
Endologix has completed enrollment in the TORUS 2 investigational device exemption (IDE) clinical study in the U.S., a press release reports. The TORUS 2 study is a prospective, single-arm trial of 188 patients to evaluate safety and effectiveness of the Torus stent…